返回 
加入收藏
2015年版《中华人民共和国药典·临床用药须知》中含黄连及其炮制品成方制剂收载情况分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 2015年版《中华人民共和国药典·临床用药须知》中含黄连及其炮制品成方制剂收载情况分析 |
| TITLE： | |
| 摘要： | 目的：为规范含黄连及其炮制品成方制剂的合理应用提供参考。方法：查阅2015年版《中华人民共和国药典·临床用药须知》（中药成方制剂卷）一书，对其中含黄连及其炮制品成方制剂的收载情况进行汇总、分析。结果与结论：2015年版《中华人民共和国药典·临床用药须知》（中药成方制剂卷）中共收载含黄连及其炮制品的成方制剂127种，其中内科、外科、妇科、儿科、皮肤科、眼科、咽喉科、口腔科、骨伤科制剂分别有83、5、2、8、4、11、6、5、3种；含黄连片的成方制剂有120种（占94.49％），含酒黄连、姜黄连、萸黄连的成方制剂分别有2、4、1种；以黄连为君、臣、佐药的成方制剂分别有39、59、29种，以清热燥湿、泻火解毒的功效为主（104种，占81.89％）。主要品种包括麝香牛黄丸、葛根岑连片、开胃健脾丸等。通过对比黄连及其炮制品的功效，发现该书收载的相关品种存在炮制品名称不规范、黄连及其炮制品标示不统一和应用不规范等现象，相关内容仍有待进一步完善。临床应加强黄连药效基础及炮制标准的相关研究，并开展相关出版物的勘察纠错工作，以有助于提高含黄连及其炮制品成方制剂的合理用药水平。 |
| ABSTRACT： | OBJECTIVE： To provide reference for standardizing rational use of set prescription preparation containing Coptis chinensis and its processed product. METHODS： By retrieving 2015 edition of Chinese Pharmacopeia·Guidelines for Clinical Drug Use（volume of TCM set prescription）， the inclusion of set prescription preparation containing C. chinensis and its processed product were summarized and analyzed. RESULTS&CONCLUSIONS： There were 127 set prescription preparations containing C. chinensis and its processed product included in 2015 edition of Chinese Pharmacopeia·Guidelines for Clinical Drug Use（volume of TCM set prescription）， among which， there were 83， 5， 2， 8， 4， 11， 6， 5 and 3 set prescription preparations for internal medicine， surgery， gynecology， pediatrics， dermatology， ophthalmology， pharyngology， stomatology， orthopedics and traumatology， respectively. There were 120 set prescription preparations containing C. chinensis（94.49％）， 2， 4 and 1 set prescription preparations containing prepared C. chinensis with vino， prepared C. chinensis with ginger and prepared C. chinensis with Euodia rutaecarpa， respectively. There were 39， 59 and 29 kinds of set prescription preparations with C. chinensis as main symptoms medicine， assists medicine and complication medicine， which were mainly for clearing heat， drying dampness， purging fire and detoxifying（104 kinds， 81.89％）. Main types included Shexiang niuhuang pills， Gegen cenlian tablets， Kaiwei jianpi pills， etc. By comparing the efficacy of C. chinensis and its processed product， it was found that the names of processed products were not standardized， the labeling of C. chinensis and its processed products were not uniform and the application was not standardized； the related contents still needed to be further improved. It is necessary to strengthen the research on the pharmacodynamic basis and processing standard of C. chinensis and carry out the investigation and correction of relevant publications in order to help improve the rational drug use level of set prescription preparations containing C. chinensis and its processed products. |
| 期刊： | 2019年第30卷第10期 |
| 作者： | 马彦江，于兰兰，王娇，陈天朝 |
| AUTHORS： | MA Yanjiang，YU Lanlan，WANG Jiao，CHEN Tianchao |
| 关键字： | 2015年版《中华人民共和国药典·临床用药须知》；黄连；炮制品；成方制剂；收载情况；合理用药 |
| KEYWORDS： | 2015 edition of Chinese Pharmacopeia·Guidelines for Clinical Drug Use； Coptis chinensis； Processed product； Set prescription preparations； Inclusion； Rational drug use |
| 阅读数： | 1167 次 |
| 本月下载数： | 11 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
